Merck (NYSE:MRK) commences the U.S. commercial launch of Ontruzant (trastuzumab-dttb), a biosimilar to Roche’s (OTCQX:RHHBY) breast cancer med Herceptin.
The wholesale acquisition cost (WAC) is ~$1,325
for the 150 mg single-dose vial and ~$3,709 for the 420 mg multiple-dose
vial, about a 15% discount from Roche’s product.
https://seekingalpha.com/news/3560766-merck-launches-herceptin-biosimilar-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.